World running out of antibiotics, WHO warns

Image
IANS Geneva
Last Updated : Sep 20 2017 | 11:57 AM IST

Antibiotics that are currently in clinical development are insufficient to combat the growing threat of antimicrobial resistance, a World Health Organisation (WHO) report said.

Most of the drugs currently in the clinical phase are modifications of existing classes of antibiotics and are only short-term solutions, WHO said.

There are, however, very few potential treatment options. The growing resistant infections pose the greatest threat to health, including drug-resistant tuberculosis (TB) which kills around 250,000 people each year.

There are also very few oral antibiotics in the pipeline, yet these are essential formulations for treating infections outside hospitals or in resource-limited settings, the report said.

"Antimicrobial resistance is a global health emergency that will seriously jeopardise progress in modern medicine," Tedros Adhanom Ghebreyesus, Director-General of WHO, said in a statement on Wednesday.

"There is an urgent need for more investment in research and development for antibiotic-resistant infections including TB, otherwise we will be forced back to a time when people feared common infections and risked their lives from minor surgery," Ghebreyesus added.

Besides TB, the WHO has also identified 12 classes of priority pathogens -- including common infections like pneumonia or urinary tract infections -- that are increasingly resistant to existing antibiotics and urgently in need of new treatments.

Among the newly identified 51 new antibiotics and biologicals in clinical development, only eight are classed by WHO as innovative treatments that will add value to the current antibiotic treatment arsenal, it said.

"Pharmaceutical companies and researchers must urgently focus on new antibiotics against certain types of extremely serious infections that can kill patients in a matter of days because we have no line of defence," noted Suzanne Hill, Director of the Department of Essential Medicines at WHO.

--IANS

rt/in/vm

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 20 2017 | 11:46 AM IST

Next Story